DOCSLIB.ORG

Exempt Anabolic Steroids (21 CFR § 1308.33 and 21 CFR § 1308.34)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Exempt Anabolic Steroids (21 CFR § 1308.33 and 21 CFR § 1308.34) Exempt Anabolic Steroids (21 CFR § 1308.33 and 21 CFR § 1308.34) November 5, 2020 Drug Enforcement Administration Diversion Control Division Drug and Chemical Evaluation Section Telephone: (571) 362-3249 E-mail: [email protected] Exempt Anabolic Steroids Trade Name Company NDC # Form Ingredients Quantity Andro-Estro 90-4 Rugby Laboratories, 0536-1605 Vial Testosterone enanthate; Estradiol valerate 90 mg/mL; 4 mg/mL Rockville Centre, NY Androgyn L.A. Forest Pharmaceuticals, St. 0456-1005 Vial Testosterone enanthate; Estradiol valerate 90 mg/mL; 4 mg/mL Louis, MO Component E-H in process Ivy Laboratories, Inc., Pail or drum Testosterone propionate; Estradiol benzoate 10 parts; 1 part granulation Overland Park, KS Component E-H in process Ivy Laboratories, Inc., Pail Testosterone propionate; Estradiol benzoate 25 mg/2.5 mg/pellet pellets Overland Park, KS Component TE-S in process Ivy Laboratories, Inc., Pail or drum Trenbolone acetate; Estradiol USP 5 parts; 1 part granulation Overland Park, KS Component TE-S in process Ivy Laboratories, Inc., Pail Trenbolone acetate; Estradiol USP 120 mg/24 mg/pellet pellets Overland Park, KS depANDROGYN Forest Pharmaceuticals, St. 0456-1020 Vial Testosterone cypionate; Estradiol cypionate 50 mg/mL; 2 mg/mL Louis, MO Depo-Testadiol The Upjohn Company, 0009-0253 Vial Testosterone cypionate; Estradiol cypionate 50 mg/mL; 2 mg/mL Kalamazoo, MI depTESTROGEN Martica Pharmaceuticals, 51698-257 Vial Testosterone cypionate; Estradiol cypionate 50 mg/mL; 2 mg/mL Phoenix, AZ DEPTO-T.E. Quality Research Pharm., 52765-257 Vial Testosterone cypionate; Estradiol cypionate 50 mg/mL; 2 mg/mL Carmel, IN Duomone Wintec Pharmaceutical, 52047-360 Vial Testosterone enanthate; Estradiol valerate 90 mg/mL; 4 mg/mL Pacific, MO DUO-SPAN II Primedics Laboratories, 0684-0102 Vial Testosterone cypionate; Estradiol cypionate 50 mg/mL; 2 mg/mL Gardena, CA DURATESTRIN W. E. Hauck, Alpharetta, GA 43797-016 Vial Testosterone cypionate; Estradiol cypionate 50 mg/mL; 2 mg/mL Essian Pharmaceutics International TB Esterified estrogens; Methyltestosterone 1.25 mg; 2.5 mg Inc., Hunt Valley, MD Essian H.S. Pharmaceutics International TB Esterified estrogens; Methyltestosterone 0.625 mg; 1.25 mg Inc., Hunt Valley, MD Esterified Estrogens and ECI Pharmaceuticals LLC TB Esterified estrogens; Methyltestosterone 1.25 mg; 2.5 mg Methyltestosterone 1.25 mg/2.5 mg D.S. Page 1 Drug Enforcement Administration Last exemption granted on June 15, 2020 (85 FR 36148) Exempt Anabolic Steroids Trade Name Company NDC # Form Ingredients Quantity Esterified Estrogens and ECI Pharmaceuticals LLC TB Esterified estrogens; Methyltestosterone 0.625 mg; 1.25 mg Methyltestosterone 0.625mg/1.25mg H.S. Esterified Estrogens and Interpharm, Inc., TB Esterified estrogens; Methyltestosterone 0.625 mg; 1.25 mg Methyltestosterone, USP (0.625 mg/1.25mg) Esterified Estrogens and Interpharm, Inc. TB Esterified estrogens; Methyltestosterone 1.25 mg; 2.5 mg Methyltestosterone, USP (1.25 mg/2.5 mg) Esterified Estrogens/ ANDAPharm, LLC TB Esterified estrogens; Methyltestosterone 0.625 mg; 1.25 mg Methyltestosterone, (0.625 mg/1.25 mg) Tablet Esterified Estrogens/ ANDAPharm, LLC TB Esterified estrogens; Methyltestosterone 1.25 mg; 2.5 mg Methyltestosterone, (1.25 mg/2.5 mg) Tablet Estratest Solvay Pharmaceuticals, 0032-1026 TB Esterified estrogens; Methyltestosterone 1.25 mg; 2.5 mg Marietta, GA Estratest H.S. Solvay Pharmaceuticals, 0032-1023 TB Esterified estrogens; Methyltestosterone 0.625 mg; 1.25 mg Marietta, GA Menogen Sage Pharmaceuticals, 59243-570 TB Esterified estrogens; Methyltestosterone 1.25 mg; 2.5 mg Shreveport, LA Menogen HS Sage Pharmaceuticals, 59243-560 TB Esterified estrogens; Methyltestosterone 0.625 mg; 1.25 mg Shreveport, LA Methyltestosterone and Lannett Company, Inc. TB Esterified estrogens; Methyltestosterone 1.25 mg; 2.5 mg Esterified Estrogens (2.5 mg/1.25 mg) Methyltestosterone and Lannett Company, Inc. TB Esterified estrogens; Methyltestosterone 0.625 mg; 1.25 mg Esterified Estrogens (Half Strength) (1.25 mg/0.625 mg) PAN ESTRA TEST Pan American Labs; 0525-0175 Vial Testosterone cypionate; Estradiol cypionate 50 mg/mL; 2 mg/mL Covington, LA Premarin with Ayerst Labs Inc., New York, 0046-0878 TB Conjugated estrogens; Methyltestosterone 0.625 mg; 5.0 mg Methyltestosterone NY Premarin with Ayerst Labs Inc., New York, 0046-0879 TB Conjugated estrogens; Methyltestosterone 1.25 mg; 10.0 mg Methyltestosterone NY Page 2 Drug Enforcement Administration Last exemption granted on June 15, 2020 (85 FR 36148) Exempt Anabolic Steroids Trade Name Company NDC # Form Ingredients Quantity Synovex H in-process bulk Syntex Animal Health, Palo Drum Testosterone propionate; Estradiol benzoate 25 mg; 2.5 mg/pellet pellets Alto, CA Synovex H in-process Syntex Animal Health, Palo Drum Testosterone propionate; Estradiol benzoate 10 part; 1 part granulation Alto, CA Synovex Plus in-process bulk Fort Dodge Animal Health, Drum Trenbolone acetate; Estradiol benzoate 25 mg; 3.5 mg/pellet pellets Fort Dodge, IA Synovex Plus in-process Fort Dodge Animal Health, Drum Trenbolone acetate; Estradiol benzoate 25 parts; 3.5 parts granulation Fort Dodge, IA Syntest D.S. Syntho Pharmaceuticals, Inc. 66576-231 TB Esterified estrogens; Methyltestosterone 1.25 mg; 2.5 mg Syntest H.S. Syntho Pharmaceuticals, Inc. 66576-230 TB Esterified estrogens; Methyltestosterone 0.625 mg; 1.25 mg TEST-ESTRO Cypionates Rugby Laboratories, 0536-9470 Vial Testosterone cypionate; Estradiol cypionate 50 mg/mL; 2 mg/mL Rockville Centre, NY Testoderm 4 mg/d Alza Corp., Palo Alto, CA 17314- Patch Testosterone 10 mg 4608 Testoderm 6 mg/d Alza Corp., Palo Alto, CA 17314- Patch Testosterone 15 mg 4609 Testoderm in-process film Alza Corp., Palo Alto, CA Sheet Testosterone 0.25 mg/cm2 Testoderm with Adhesive 4 Alza Corp., Palo Alto, CA Export only Patch Testosterone 10 mg mg/d Testoderm with Adhesive 6 Alza Corp., Palo Alto, CA 17314- Patch Testosterone 15 mg mg/d 2836 Testoderm with Adhesive in- Alza Corp., Palo Alto, CA Sheet Testosterone 0.25 mg/cm2 process film Testosterone Cyp 50 Estradiol I.D.E.-Interstate, 0814-7737 Vial Testosterone cypionate; Estradiol cypionate 50 mg/mL; 2 mg/mL Cyp 2 Amityville, NY Testosterone Best Generics, North Miami 54274-530 Vial Testosterone cypionate; Estradiol cypionate 50 mg/mL; 2 mg/mL Cypionate/Estradiol Cypionate Beach, FL Injection Testosterone Goldline Labs, Ft. 0182-3069 Vial Testosterone cypionate; Estradiol cypionate 50 mg/mL; 2 mg/mL Cypionate/Estradiol Cypionate Lauderdale, FL Injection Page 3 Drug Enforcement Administration Last exemption granted on June 15, 2020 (85 FR 36148) Exempt Anabolic Steroids Trade Name Company NDC # Form Ingredients Quantity Testosterone Schein Pharmaceuticals, Port 0364-6611 Vial Testosterone cypionate; Estradiol cypionate 50 mg/mL; 2 mg/mL Cypionate/Estradiol Cypionate Washington, NY Injection Testosterone Steris Labs Inc. Phoenix, AZ 0402-0257 Vial Testosterone cypionate; Estradiol cypionate 50 mg/mL; 2 mg/mL Cypionate/Estradiol Cypionate Injection Testosterone Goldline Labs, Ft. 0182-3073 Vial Testosterone enanthate; Estradiol valerate 90 mg/mL; 4 mg/mL Enanthate/Estradiol Valerate Lauderdale, FL Injection Testosterone Schein Pharmaceuticals, Port 0364-6618 Vial Testosterone enanthate; Estradiol valerate 90 mg/mL; 4 mg/mL Enanthate/Estradiol Valerate Washington, NY Injection Testosterone Steris Labs Inc. Phoenix, AZ 0402-0360 Vial Testosterone enanthate; Estradiol valerate 90 mg/mL; 4 mg/mL Enanthate/Estradiol Valerate Injection Testosterone Ophthalmic Allergan, Irvine, CA Ophthalmic Testosterone ≤0.6% w/v Solutions solution Tilapia Sex Reversal Feed Wilbur-Ellis Nutrition LLC, Plastic Bags Methyltestosterone 60 mg/kg fish feed (Investigational) Buhl, ID Page 4 Drug Enforcement Administration Last exemption granted on June 15, 2020 (85 FR 36148) .
Load more

Recommended publications
  • PPE Requirements Hazardous Drug Handling
    This document’s purpose is only to provide general guidance. It is not a definitive interpretation for how to comply with DOSH requirements. Consult the actual NIOSH hazardous drugs list and program regulations in entirety to understand all specific compliance requirements. Minimum PPE Required Minimum PPE Required Universal (Green) - handling and disposed of using normal precautions. PPE Requirements High (Red) - double gloves, gown, eye and face protection in Low (Yellow) - handle at all times with gloves and appropriate engineering Hazardous Drug Handling addition to any necessary controls. engineering controls. Moderate (Orange) -handle at all times with gloves, gown, eye and face protection (with splash potential) and appropirate engineering controls. Tablet Open Capsule Handling only - Contained Crush/Split No alteration Crush/Split Dispensed/Common Drug Name Other Drug Name Additional Information (Formulation) and (NIOSH CATEGORY #) Minimum PPE Minimum PPE Minimum PPE Minimum PPE Required required required required abacavir (susp) (2) ziagen/epzicom/trizivir Low abacavir (tablet) (2) ziagen/epzicom/trizivir Universal Low Moderate acitretin (capsule) (3) soriatane Universal Moderate anastrazole (tablet) (1) arimidex Low Moderate High android (capsule) (3) methyltestosterone Universal Moderate apomorphine (inj sq) (2) apomorphine Moderate arthotec/cytotec (tablet) (3) diclofenac/misoprostol Universal Low Moderate astagraf XL (capsule) (2) tacrolimus Universal do not open avordart (capsule) (3) dutasteride Universal Moderate azathioprine
    [Show full text]
  • Bipolar Androgen Therapy (BAT) in Men with Prostate Cancer
    Bipolar Androgen Therapy (BAT) in men with prostate cancer Samuel Denmeade, MD Professor of Oncology, Urology and Pharmacology The Johns Hopkins University School of Medicine, Baltimore, MD Presentation Overview • Androgen and Androgen Signaling 101 • Rationale For Bipolar Androgen Therapy (BAT) • Results from the RESTORE study testing BAT in Castration Resistant Prostate Cancer • The multi-center TRANSFORMER Trial • Future Directions • Results of BATMAN trial testing BAT as part of Intermittent Hormone Therapy strategy Testosterone Replacement Anabolic Steroids Trenbolone Acetate (Fina-Finaplix H pellets) High Dose Testosterone as Treatment for Prostate Cancer What Are Androgens? • Steroid hormone which can bind to Androgen Receptor – Testosterone, Dihydrotestosterone (DHT), DHEA, Androstenedione… • Sexual Differentiation – Needed to make a Male (Female is Default) • Primary Sex Characteristics: – Spermatogenesis – Accessory Sex Tissue Maintenance • Penis, Prostate... • Secondary Sex Characteristics: – Bone density – Muscle mass – Libido – Hair growth – Hematopoiesis What is a Steroid Hormone? Testosterone (T) Dihydrotestosterone (DHT) Estrogen How are Androgens Made? Androgen Receptor Signaling 101 Androgen Active Androgen Receptor (Testosterone) Androgen Receptor How Do Androgens Effect the Prostate Cell? NTD- Signaling Part DBD- DNA Binding Part LBD- Androgen Binding Part Cytoplasm Cell Nucleus Binds and activates genes: -Cell Growth -Cell Survival -Make prostate stuff like PSA, Acid Phosphatase, etc. DNA The Devilish Prostate • Physiologic
    [Show full text]
  • Comparison of the Effects of High Dose Testosterone and 19-Nortestosterone to a Replacement Dose of Testosterone on Strength and Body Composition in Normal Men
    J. Steroid Biochem. Molec. Biol. Vol. 40, No. 4-6, pp. 607~12, 1991 0960-0760/91 $3.00 + 0.00 Printed in Great Britain Pergamon Press plc COMPARISON OF THE EFFECTS OF HIGH DOSE TESTOSTERONE AND 19-NORTESTOSTERONE TO A REPLACEMENT DOSE OF TESTOSTERONE ON STRENGTH AND BODY COMPOSITION IN NORMAL MEN KARL E. FRIEDL,* JOSEPH R. DETTORI, CHARLES J. HANNAN JR, TROY H. PATIENCE and STEPHENR. PLYMATE Exercise Physiology Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA and Department of Clinical Investigation, Madigan Army Medical Center, Tacoma, WA, U.S.A. Summary--We examined the extent to which supraphysiological doses of androgen can modify body composition and strength in normally virilized men. In doubly blind tests, 30 healthy young men received testosterone enanthate (TE) or 19-nortestosterone decanoate (ND), at 100mg/wk or 300mg/wk for 6 weeks. The TE-100mg/wk group served as replacement dose comparison, maintaining pretreatment serum testosterone levels, while keeping all subjects blinded to treatment, particularly through reduction in testicular volumes. Isokinetic strength measurements were made for the biceps brachii and quadriceps femoris muscle groups before treatment and 2-3 days after the 6th injection. Small improvements were noted in all groups but the changes were highly variable; a trend to greater and more consistent strength gain occurred in the TE-300mg/wk group. There was no change in weight for TE-100 mg/wk but an average gain of 3 kg in each of the other groups. No changes in 4 skinfold thicknesses or in estimated percent body fat were observed.
    [Show full text]
  • Albany-Molecular-Research-Regulatory
    PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF A Abiraterone Malta • Benztropine Mesylate Cedarburg • Adenosine Rozzano - Quinto de' Stampi • • * Betaine Citrate Anhydrous Bon Encontre • Betametasone-17,21- Alcaftadine Spain Spain • • Dipropionate Sterile • Alclometasone-17, 21- Spain Betamethasone Acetate Spain Dipropionate • • Altrenogest Spain • • Betamethasone Base Spain Amphetamine Aspartate Rensselaer Betamethasone Benzoate Spain * Monohydrate Milled • Betamethasone Valerate Amphetamine Sulfate Rensselaer Spain * • Acetate Betamethasone-17,21- Argatroban Rozzano - Quinto de' Stampi Spain • • Dipropionate • • • Atenolol India • • Betamethasone-17-Valerate Spain • • Betamethasone-21- Atracurium Besylate Rozzano - Quinto de' Stampi Spain • Phosphate Disodium Salt • • Bromfenac Monosodium Atropine Sulfate Cedarburg Lodi * • Salt Sesquihydrate • • Azanidazole Lodi Bromocriptine Mesylate Rozzano - Quinto de' Stampi • • • • • Azelastine HCl Rozzano - Quinto de' Stampi • • Budesonide Spain • • Aztreonam Rozzano - Valle Ambrosia • • Budesonide Sterile Spain • • B Bamifylline HCl Bon Encontre • Butorphanol Tartrate Cedarburg • Beclomethasone-17, 21- Spain Capecitabine Lodi Dipropionate • C • 2 *Please contact our Accounts Managers in case you are interested in this API. 3 PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF Dexamethasone-17,21- Carbimazole Bon Encontre Spain • Dipropionate
    [Show full text]
  • MENEST ® Brand of Esterified Estrogens Tablets, USP
    PRESCRIBING INFORMATION MENEST ® brand of esterified estrogens tablets, USP WARNINGS 1. ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA. Three independent case control studies have shown an increased risk of endometrial cancer in postmenopausal women exposed to exogenous estrogens for prolonged periods.1–3 This risk was independent of the other known risk factors for endometrial cancer. These studies are further supported by the finding that incidence rates of endometrial cancer have increased sharply since 1969 in eight different areas of the United States with population-based cancer reporting systems, an increase which may be related to the rapidly expanding use of estrogens during the last decade.4 The three case control studies reported that the risk of endometrial cancer in estrogen users was about 4.5 to 13.9 times greater than in nonusers. The risk appears to depend on both duration of treatment1 and on estrogen dose.3 In view of these findings, when estrogens are used for the treatment of menopausal symptoms, the lowest dose that will control symptoms should be utilized and medication should be discontinued as soon as possible. When prolonged treatment is medically indicated, the patient should be reassessed on at least a semiannual basis to determine the need for continued therapy. Although the evidence must be considered preliminary, one study sug- gests that cyclic administration of low doses of estrogen may carry less risk than continuous administration3; it therefore appears prudent to utilize such a regimen. Close clinical surveillance of all women taking estrogens is important. In all cases of undiagnosed persistent or recurring abnormal vaginal bleeding, adequate diagnostic measures should be undertaken to rule out malignancy.
    [Show full text]
  • Steroids 78 (2013) 44–52
    Steroids 78 (2013) 44–52 Contents lists available at SciVerse ScienceDirect Steroids journal homepage: www.elsevier.com/locate/steroids Alternative long-term markers for the detection of methyltestosterone misuse ⇑ C. Gómez a,b, O.J. Pozo a, J. Marcos a,b, J. Segura a,b, R. Ventura a,b, a Bioanalysis Research Group, IMIM-Hospital del Mar, Barcelona, Spain b Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain article info abstract Article history: Methyltestosterone (MT) is one of the most frequently detected anabolic androgenic steroids in doping Received 21 May 2012 control analysis. MT misuse is commonly detected by the identification of its two main metabolites Received in revised form 28 September excreted as glucuronide conjugates, 17a-methyl-5a-androstan-3a,17b-diol and 17a-methyl-5b-andro- 2012 stan-3a,17b-diol. The detection of these metabolites is normally performed by gas chromatography–mass Accepted 10 October 2012 spectrometry, after previous hydrolysis with b-glucuronidase enzymes, extraction and derivatization Available online 2 November 2012 steps. The aim of the present work was to study the sulphate fraction of MT and to evaluate their potential to improve the detection of the misuse of the drug in sports. MT was administered to healthy volunteers Keywords: and urine samples were collected up to 30 days after administration. After an extraction with ethyl ace- Methyltestosterone Sulphate tate, urine extracts were analysed by liquid chromatography tandem mass spectrometry using electro- Metabolism spray ionisation in negative mode by monitoring the transition m/z 385 to m/z 97. Three diol sulphate LC–MS/MS metabolites (S1, S2 and S3) were detected.
    [Show full text]
  • Expression of Recombinant Human Androgen Receptor and Its Use for Screening Methods
    Institut für Physiologie FML Weihenstephan Technische Universität München Expression of recombinant human androgen receptor and its use for screening methods Ellinor Rose Sigrid Bauer Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ.-Prof. Dr. B. Hock Prüfer der Dissertation: Univ.-Prof. Dr. H. H. D. Meyer Univ.-Prof. Dr. H. Sauerwein (Rheinische Friedrich-Wilhelms-Universität Bonn) Die Dissertation wurde am 31.10.2002 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 03.12.2002 angenommen. Introduction Content 1. INTRODUCTION ..................................................................................................................................... 5 1.1. ENDOCRINE DISRUPTERS 5 1.2. ANDROGENS AND ANTIANDROGENS 7 1.2.1. DEFINITIONS 7 1.2.2. MODE OF ACTION 8 1.3. STRUCTURES OF ENDOCRINE DISRUPTERS 10 1.4. STRATEGIES FOR MONITORING ANDROGEN ACTIVE SUBSTANCES 13 1.4.1. IN VIVO METHODS 13 1.4.2. IN VITRO METHODS 15 1.5. OBJEKTIVE OF THE STUDIES 18 2. MATERIALS AND METHODS ................................................................................................................. 19 2.1. PREPARATION OF RECEPTORS 19 2.2. ASSAY SYSTEMS 19 2.2.1. IN SOLUTION AR ASSAY 19 2.2.2. IMMUNO-IMMOBILISED RECEPTOR ASSAY (IRA) 20 2.2.3. PR AND SHBG ASSAYS 21 2.2.4. DATA EVALUATION 21 2.3. ANALYTES 22 3. RESULTS AND DISCUSSION ................................................................................................................. 23 3.1. DEVELOPMENT OF NEW ASSAY SYSTEMS 23 3.1.1. BAR ASSAY 23 3.1.2. CLONING OF THE HUMAN AR AND PRODUCTION OF FUNCTIONAL PROTEIN 24 3.1.3. DEVELOPMENT OF A SCREENING ASSAY ON MICROTITRE PLATES (IRA) 25 3.2.
    [Show full text]
  • Estradiol-17Β Pharmacokinetics and Histological Assessment Of
    animals Article Estradiol-17β Pharmacokinetics and Histological Assessment of the Ovaries and Uterine Horns following Intramuscular Administration of Estradiol Cypionate in Feral Cats Timothy H. Hyndman 1,* , Kelly L. Algar 1, Andrew P. Woodward 2, Flaminia Coiacetto 1 , Jordan O. Hampton 1,2 , Donald Nickels 3, Neil Hamilton 4, Anne Barnes 1 and David Algar 4 1 School of Veterinary Medicine, Murdoch University, Murdoch 6150, Australia; [email protected] (K.L.A.); [email protected] (F.C.); [email protected] (J.O.H.); [email protected] (A.B.) 2 Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Melbourne 3030, Australia; [email protected] 3 Lancelin Veterinary Hospital, Lancelin 6044, Australia; [email protected] 4 Department of Biodiversity, Conservation and Attractions, Locked Bag 104, Bentley Delivery Centre 6983, Australia; [email protected] (N.H.); [email protected] (D.A.) * Correspondence: [email protected] Received: 7 September 2020; Accepted: 17 September 2020; Published: 21 September 2020 Simple Summary: Feral cats (Felis catus) have a devastating impact on Australian native fauna. Several programs exist to control their numbers through lethal removal, using tools such as baiting with toxins. Adult male cats are especially difficult to control. We hypothesized that one way to capture these male cats is to lure them using female cats. As female cats are seasonal breeders, a method is needed to artificially induce reproductive (estrous) behavior so that they could be used for this purpose year-round (i.e., regardless of season).
    [Show full text]
  • TESTOSTERONE and ANABOLIC STEROIDS Summary Testosterone Is a Hormone Naturally Produced by the Body
    FactSHEET TESTOSTERONE AND ANABOLIC STEROIDS Summary Testosterone is a hormone naturally produced by the body. Low levels of testosterone can cause symptoms of fatigue, malaise, loss of sex drive, and loss of muscle tissue. These symptoms can often be treated with synthetic testosterone. Anabolic steroids are compounds related to testosterone. Using synthetic testosterone or anabolic steroids may help people with HIV-related wasting gain weight, especially muscle mass. What is testosterone? Sometimes HIV-positive men develop low testosterone levels which can cause symptoms Although it is usually thought of as a male of fatigue, muscle wasting, low (or no) sex hormone, women’s bodies also make drive, impotence, and loss of facial or body testosterone, but at much lower levels than hair. This condition is called hypogonadism. men’s. Testosterone has two different effects on Hormone replacement therapy with synthetic the body: anabolic effects which promote growth testosterone may help to relieve those and muscle building, and androgenic effects symptoms. which develop the male sex organs and secondary sex characteristics such as deepening HIV-positive women may also develop low of the voice and growth of facial hair. testosterone levels and experience symptoms of fatigue, loss of sex drive, and a decreased sense of well-being. Because the androgenic What are anabolic steroids? (masculinizing) effects of testosterone and Anabolic steroids are synthetic compounds anabolic steroids can be permanent, that resemble the natural hormone researchers have been cautious about studying testosterone. Makers of anabolic steroids these drugs in women. change the testosterone molecule slightly to 2. To treat weight loss change the balance of androgenic and anabolic effects, which can allow these drugs to build Anabolic steroids can be used in order to build muscle with fewer masculinizing effects.
    [Show full text]
  • Structure and Origin of Uterine and Extragenital L=Ibroids Induced
    Structure and Origin of Uterine and Extragenital l=ibroids Induced Experimentally in the Guinea Pig by Prolonged Administration of Estrogens* Alexander Lipschotz, M.D., and Louis Vargas, Jr., M.D. (From Department o/ Experimental Medicine, National Health Service o/the Republic o/Chile, Santiago, Chile) (Received for publication December 13, x94o) The purpose of this communication is to present the These experimentally induced abdominal tumors findings of a detailed microscopical study of the sites present a smooth surface formed of a capsule com- of origin and stages of development of the subserous posed of flattened superficial cells (Plate 2, Figs. 2-A fibroid tumors induced in guinea pigs by prolonged and 2-B). The cells beneath the capsule resemble administration of estrogens. Details of treatment of fibroblasts. These cells have definite boundaries or the animals are given in the explanations of Plates I- 5. they are separated from each other by collagenous Subserous uterine tumors which can be induced in fibers (Plate 4, Fig. ix-C). guinea pigs by prolonged administration of estrogens, The masses of fibroid tumors arising from the apex as described by Nelson (26, 27), were found to be of the uterine horn may enclose the tubes or large fibroids. Lipschiitz, Iglesias, and Vargas (i3, 18, 22) tubal cysts. The demarcation between the muscular have shown that extragenital tumors in the abdominal coat of the tube and the tumor is not always sharp. cavity, induced by estrogens, also were fibroids. The In some instances, especially when the apical fibroid localization of these tumo~:s at various sites on the is small, the tumor is in close contact with an abun- uterus, pancreas, kidney, spleen, etc., have been de- dance of smooth muscle and adipose tissue (Plate 2, scribed by Iglesias (5), Vargas and Lipschiitz (32), Fig.
    [Show full text]
  • New Pharmacological Treatments for Equine Reproductive Management
    New Pharmacological Treatments for Equine Reproductive Management P. J. Burns, Ph.D.11,2,3,4, D. L. Thompson, Jr, Ph.D.5, W. A. Storer Ph.D.5 R. Gilley B.S1,2,3., C. Morrow, D.V.M.3, J. Abraham, B. S. 7 & R. H. Douglas, Ph.D. 1,2,3 1BioRelease Technologies LLC, Birmingham, AL 2BET Pharm, Lexington, KY 3 Mt Laurel Veterinary Pharmacy, Birmingham, 4Burns BioSolutions INC, Lexington, KY 5Animal Sciences Department, Louisiana State University, Baton Rouge, LA 6 Mobile Veterinary Practice, Amarillo, Tx, 7 Abraham Equine, Mendota Ranch, Canadian,Tx Introduction Loy (1970) reported that only 55% of mares bred annually produce live foals. Recent data from The Jockey Club (2006) indicate that only 37,025 of 64,123 (57.7%) of thoroughbred mares bred during 2005 produced live foals. This is considerably lower than foaling rates of 71 to 85%, which are reported on farms where extensive reproductive management is used. Overall, reproductive management has not improved much in the last 30 years. The long estrus period, with ovulation at any time from 1 to 10 days after the beginning of estrus, has made reproductive management of cyclic mares time-consuming, expensive and most importantly, inefficient. Furthermore, the confusion associated with the long and variable transition from anestrous to cyclicity in mares greatly magnifies the complexity of efficient reproductive management for this category of mares. There is a need to develop and capitalize on controlled breeding programs for the horse industry based on new advances in the understanding of cost effective hormonal control of reproduction in mares and stallions.
    [Show full text]
  • Estrogen Agents, Oral-Transdermal
    GEORGIA MEDICAID FEE-FOR-SERVICE ESTROGEN AGENTS, ORAL - TRANSDERMAL PA SUMMARY Preferred Non-Preferred Oral Estrogens Estradiol generic n/a Menest (esterified estrogens) Premarin (estrogens, conjugated) Oral Estrogen/Progestin Combinations Angeliq (drospirenone/estradiol) Bijuva (estradiol/progesterone) Estradiol/norethindrone and all generics for Activella Norethindrone/ethinyl estradiol and all generics for Femhrt Low Dose 0.5/2.5 (norethindrone/ethinyl Femhrt Low Dose estradiol) Jinteli and all generics for Femhrt 1/5 (norethindrone/ethinyl estradiol) Prefest (estradiol/norgestimate) Premphase (conjugated estrogens/medroxyprogesterone) Prempro (conjugated estrogens/medroxyprogesterone) Topical Estrogens Alora (estradiol transdermal patch) Divigel (estradiol topical gel) Estradiol transdermal patch (generic Climara) Elestrin (estradiol topical gel) Evamist (estradiol topical spray solution) Estradiol transdermal patch (generic Vivelle-Dot) Menostar (estradiol transdermal patch) Minivelle (estradiol transdermal patch) Vivelle-Dot (estradiol transdermal patch) Topical Estrogens/Progestin Combination Climara Pro (estradiol/levonorgestrel transdermal patch) n/a Combipatch (estradiol/norethindrone transdermal patch) Oral Selective Estrogen Receptor Modulator (SERMs) Raloxifene generic Duavee (conjugated estrogens/bazedoxifene) Osphena (ospemifene) LENGTH OF AUTHORIZATION: 1 year PA CRITERIA: Bijuva ❖ Approvable for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with an intact uterus who have experienced inadequate response, allergies, contraindications, drug-drug interactions or intolerable side effects to at least two preferred oral estrogen/progestin combination products. Revised 6/29/2020 Norethindrone/Ethinyl Estradiol and All Generics for Femhrt Low Dose ❖ Prescriber must submit a written letter of medical necessity stating the reasons at least two preferred oral estrogen/progestin combination products, one of which must be brand Femhrt Low Dose, are not appropriate for the member.
    [Show full text]